Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | NCK1 | P16333 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701987 | 0.91 | CYP1A2 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL2701718 | 0.91 | CYP1A2 (0.54) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL645484 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL18317243 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL18317357 | 0.79 | CYP1A2 (0.44) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL18317633 | 0.78 | CYP1A2 (0.45) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL18317612 | 0.77 | CYP1A2 (0.44) | CYP1A2CYP2A6TDP1ALDH1A1HSD17B10 | |
| SCHEMBL11612286 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP2A6 | |
| SCHEMBL559813 | 0.75 | — | — | |
| SCHEMBL70257 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2778160-B1 | CYCLIC AZINE COMPOUND HAVING NITROGEN-CONTAINING FUSED AROMATIC GROUP, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME AS CONSTITUENT COMPONENT | TOSOH CORP (JP) | 2018-01-10 | — | — | EP | claimed |
| US-9252368-B2 | Cyclic azine compound having nitrogen-containing condensed aromatic group, method for producing same, and organic electroluminescent device comprising same as constituent component | TOSOH CORPORATION (JP) | 2016-02-02 | — | — | US | claimed |
| US-20140330013-A1 | CYCLIC AZINE COMPOUND HAVING NITROGEN-CONTAINING FUSED AROMATIC GROUP, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2014-11-06 | — | — | US | claimed |
| EP-2778160-A1 | CYCLIC AZINE COMPOUND HAVING NITROGEN-CONTAINING FUSED AROMATIC GROUP, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME AS CONSTITUENT COMPONENT | Tosoh Corporation (JP) | 2014-09-17 | — | — | EP | claimed |
| US-8735577-B2 | 1,3,5-triazine derivative, process for producing same, and organic electroluminescent element comprising same as constituent component | TOSOH CORPORATION (JP) | 2014-05-27 | — | — | US | claimed |
| EP-1930329-B1 | 1,3,5-TRIAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME AS COMPONENT | TOSOH CORP (JP) | 2012-10-24 | — | — | EP | claimed |
| US-7994316-B2 | 1,3,5-triazine derivative, production method thereof and organic electroluminescence device comprising this as a composing component | TOSOH CORPORATION (JP) | 2011-08-09 | — | — | US | claimed |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | TOSOH CORPORATION (JP) | 2009-11-12 | — | — | US | claimed |
| EP-1930329-A1 | 1,3,5-TRIAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME AS COMPONENT | Tosoh Corporation (JP) | 2008-06-11 | — | — | EP | claimed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | claimed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | claimed |
| US-4125619-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1978-11-14 | — | — | US | claimed |
| US-4104392-A | N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1978-08-01 | — | — | US | claimed |
| US-4096255-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-20 | — | — | US | claimed |
| US-4073916-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4073914-A | THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-14 | — | — | US | claimed |
| US-4072744-A | SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-02-07 | — | — | US | claimed |
| US-4070457-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-24 | — | — | US | claimed |
| US-4049645-A | ANTITHROMBOTIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-09-20 | — | — | US | claimed |
| US-4036955-A | TREATMENT OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-07-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | CYP1A2 1354/4885CYP2A6 1833/4885TDP1 4579/4885 |
| US-20090281311-A1 | 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT | KCNJ2, KCNA4, KCNJ4 | CYP1A2 459/4885CYP2A6 2133/4885TDP1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.